Introduction
============

Idiosyncratic drug-induced liver injury (DILI) is a condition that symptomatically can mimic most kinds of acute and chronic liver disorders. Unlike intrinsic DILI, it cannot be predicted based on drug pharmacological action or dose. It is believed that idiosyncratic DILI occurs in one of every 10 000 to 100 000 patients taking a specific medication, with some drugs being more prone to cause DILI than others. The majority of idiosyncratic DILI cases fully recuperates after drug cessation, while 4--10% go on to develop acute liver failure ([@B5], [@B5]; [@B23]). Furthermore, DILI is a major factor in drug development discontinuations and postmarketing drug withdrawals. Despite increased interest, the cellular mechanism behind DILI is not fully understood. Previous studies have, however, demonstrated an apparent role for the immune system in various forms of idiosyncratic DILI, including higher representation of specific HLA class I and II alleles in amoxicillin-clavulanate (AC) DILI patients ([@B19]; [@B25]; [@B9]).

Natural killer (NK) cells are an integral part of the innate immune system, in particularly in the liver, with cytolytic capacity to kill cancer and infected cells. Furthermore, NK cells can contribute to inflammation and immunoregulation through their release of cytokines and subsequently also play a modifying role in adaptive immunity. The activity of NK cells is regulated by various types of cell surface receptors, such as killer Ig-like receptors (KIR). The KIR family contains both inhibitory (iKIR: 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 3DL1, 3DL2, and 3DL3) and activating (aKIR: 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, and 3DS1) receptors. Although initially believed to be an inhibitory receptor, KIR2DL4 is now considered to have both inhibitory and activating signaling domains ([@B21]). The KIR genes are highly variable, with polymorphisms on gene as well as allele levels. Both aKIRs and iKIRs are expressed on the same NK cell and the exact KIR composition varies from individual to individual. The KIR genes are generally inherited as haplotype A or B. Group A comprises six iKIRs (*2DL1, 2DL*3, *2D*L4, *3DL1, 3DL2*, and *3DL3*), one aKir (*2DS4*) and two pseudogenes (*2DP1* and *3DP1*). Any other KIR gene combination with at least one of the *KIR2DL*2, *2DL5, 3DS1, 2DS1, 2DS2, 2DS3*, or *2DS5* genes present, is referred to as group B haplotype ([@B31]). The balance of activating and inhibitory KIRs may subsequently contribute to enhanced risk of distinct diseases.

Inhibitory NK cell activity signals are mainly induced through the recognition of HLA class I ligands by iKIR receptors. KIR2DL1 binds preferentially to HLA-C allotypes characterized by a lysine in amino acid position 80 (C2 epitope), while KIR2DL3 and particularly 2DL2 have higher recognition affinity for the C1 epitope, containing an asparagine in the same position ([@B32]; [@B20]). The HLA-B alleles can be divided into allotypes containing the serological Bw4 or Bw6 public epitope, with the exception of a few B alleles that do not contain either of these epitopes ([@B10]). KIR3DL1 binds preferentially to HLA-B allotypes characterized by the Bw4 epitope, which is defined by the amino acid motifs at positions 77--83. The HLA-A alleles A^∗^23:01, A^∗^24:02, and A^∗^32:01 have also been found to contain the Bw4 epitope and subsequently can act as ligands for KIR3DL1. The KIR3DL2 receptor has been shown to bind to HLA-A3 and A11 allotypes, although the interaction appears to be highly dependent on the peptide bound to the HLA complex ([@B11]). In addition, a recent study has demonstrated that HLA-B27 can also interact with KIR3DL2, although B27 is less frequent than the HLA-A allotypes in most populations ([@B24]). The aKIR receptor ligands are less well established. It is believed that many aKIR receptors share HLA ligands with their corresponding inhibitory counterparts, but bind with lower affinity ([@B27]).

The existing variability in KIR and HLA profiles between individuals could potential result in specific profiles being more prone to certain medical conditions, as suggested for Italian *KIR2DS1* and HLA-C2 ligand carriers being more susceptible to autoimmune hepatitis ([@B18]). We have previously demonstrated that HLA alleles have an effect on AC DILI susceptibility and phenotype. As HLA class I alleles are involved in the regulation of NK cell activity through KIR receptors, and considering the increased abundance of NK cells in the liver, we aimed to evaluate the contribution of HLA class I profiles in conjunction with KIR gene repertoires to determine potential genetic predispositions for AC DILI in Spanish subjects.

Materials and Methods {#s1}
=====================

Subjects and Study Protocol
---------------------------

A total of 102 AC DILI cases were selected from those submitted to the Spanish DILI Registry, a collaborative network established in 1994 to prospectively identify cases of DILI in a standardized manner. The criteria for DILI at the time of subject inclusions in the study were: an increase in alanine transaminase (ALT) ≥3 times the upper limit of normal (xULN) or ≥2 xULN of alkaline phosphatase (ALP) or total bilirubin (TBL) ≥2 xULN if associated with elevations of ALT or ALP. However, 91% of the cases also fulfilled the more recent DILI criteria established by [@B1]: ALT ≥ 5 xULN or ALT ≥ 3 xULN + TBL ≥ 2 xULN or ALP ≥ 2 xULN. The pattern of liver injury was classified based on *R*-value calculations as previously described ([@B1]). A detailed description of the operational structure of the registry, data recording and case ascertainment has been reported elsewhere ([@B2]). As a control group, we selected 226 unrelated Spanish subjects of Caucasian descent, without previous DILI history. These controls were recruited from the Spanish Bone Marrow Donor Registry as well as hospital volunteers from the same geographic region and of similar age and gender distribution. Due to the frequent use of AC in the general population in Spain it was assumed that a large proportion of the controls would have taken AC during some stage of their lives without developing DILI.

Ethics Statement
----------------

The study protocol was approved by the local ethics committee of the coordinating center at the Hospital Universitario Virgen de la Victoria (Comité Ético de Investigación) in Málaga, Spain. All subjects who took part in the study were 18 years of age or older. All subjects gave written informed consent, which conformed with the current Helsinki Declaration, prior to study enrolment.

DNA Extraction and Genotyping
-----------------------------

Venous blood was obtained from each subject and DNA was extracted using QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Genotyping of KIRs *2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 3DLI, 3DL2, 3DL3, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DS1, 2DP1*, and *3DP1* was performed using the Lifecodes KIR-SSO typing Kit 545110R (Immucor Inc, Norcross, GA, USA) and analyzed with a Bio-Plex 200 system (Luminex xMAP, Austin, TX, USA) according to the manufacturer's instructions. Haplotype designation was determined as previously described ([@B30]). Individuals carrying only haplotype A genes (*KIR2DL1, 2DL3, 2DL4, 3DL1, 3DL2, 3DL3, 2DS4, 2DP1*, and *3DP1*) were considered as AA genotype carriers. All other KIR gene combinations were referred to as Bx genotypes, where x indicates an A or B haplotype.

Genotyping of the HLA class I (A, B, and C) loci was performed using the LABType^®^ SSO typing test (One Lambda, Canoga Park, CA, USA). Target DNA was amplified by PCR using sequence-specific primers, followed by hybridization with allele-specific oligodeoxynucleotides coupled with fluorescent phycoerythrin-labeled microspheres. The fluorescence intensity was determined with a Bio-Plex 200 system (Luminex xMAP, Austin, TX, USA). HLA alleles were assigned using the HLA-Tools software (One Lambda, Canoga Park, CA, USA). The HLA ligand groups were assigned based on the amino acid residues of the corresponding alleles. The HLA-C alleles containing an asparagine at position 80 were considered as being C1 and those with a lysine in the same position as C2. Similarly, the HLA-B alleles were classified as HLA-Bw4 and Bw6 depending on the amino acids at positions 77--83 ^[1](#fn01){ref-type="fn"}^. In addition, HLA-A^∗^23:01, A^∗^24:02, and A^∗^32:01 were also considered as Bw4 containing alleles based on previously demonstrated results ([@B26]).

Statistical Analysis
--------------------

Human leukocyte antigen allele distributions were compared between DILI patients and controls using a comparison of proportions test, a derivative of Fisher's exact test, and *p* \< 0.05 was considered to be statistically significant.

Results
=======

DILI Patient Characteristics
----------------------------

A total of 102 AC DILI patients were included in the study of which 60 were males and 42 females. The mean age at DILI onset was 59 years, ranging from 18 to 88 years. The predominant pattern of injury, based on the *R*-value calculated from the first blood sample analysis after DILI recognition, was hepatocellular (*n* = 39) followed by mixed (*n* = 34) and cholestatic (*n* = 29). Of the 102 patients two developed liver failure resulting in death or liver transplantation. Demographics, clinical, and laboratory parameters of the 102 DILI cases included in the study are outlined in **Table [1](#T1){ref-type="table"}**.

###### 

Demographics, clinical, and laboratory parameters of the 102 DILI cases included in the study.

  --------------------------------------------------- -------------------
  **Demographics**                                    
  Mean age, years (range)                             59 (18--88)
  Male/female, *n*                                    60/42
  Body mass index, mean ± SD                          26.1 ± 3.2
  **Time to DILI onset, *n***                         
  \<15 days                                           62
  15 -- 30 days                                       26
  \>30 days                                           14
  **Clinical presentation, *n***                      
  Jaundice                                            85
  Hospital admission                                  59
  **Type of liver injury, *n***                       
  Hepatocellular                                      39
  Cholestatic                                         29
  Mixed                                               34
  **Biochemical parameters^∗^, mean ± SD (median)**   
  Total bilirubin (mg/dL)                             7.6 ± 5.5 (6.7)
  ALT xULN, hepatocellular and mixed cases            18.0 ± 19.4 (9.8)
  ALP xULN, cholestatic and mixed cases               2.7 ± 1.6 (2.2)
  --------------------------------------------------- -------------------

∗

First available serum analysis after DILI onset. ALT, alanine transaminase; ALP, alkaline phosphatase; ULN, upper limit of normal.

KIR Gene Distribution
---------------------

All the 102 AC DILI patients and 226 controls were genotyped for the presence or absence of 16 KIRs, including the two pseudogenes 2DP1 and 3DP1. No significant differences were found in the distribution of individual KIR genes between patients and controls. The four framework genes *KIR3DL2, 3DL3, 3DP1*, and *2DL4* were present in all tested subjects. *KIR2DL1, 3DL1, 2DS4*, and *2DP1* were found in more than 90% of both the patient and control cohorts, while *2DS1, 2DS3, 2DS5*, and *3DS1* where the least present genes, only seen in less than 45% of the subjects (**Table [2](#T2){ref-type="table"}**). While the *KIR2DS4* gene was among the more frequently detected genes, 46 and 51% of the *KIR2DS4* carrying DILI patients and controls, respectively, were homozygous for a 22 base pair deletion, which produces a non-functional receptor, and 37% in both subgroups were found to be heterozygous for the same mutation.

###### 

Distribution of KIR genes in 102 Spanish amoxicillin-clavulanate--induced liver injury patients and 226 controls.

                         2DL1       2DL2       2DL3       2DL4        2DL5       3DL1       3DL2        3DL3        2DS1      2DS2       2DS3      2DS4       2DS5      3DS1      2DP1       3DP1
  ---------------------- ---------- ---------- ---------- ----------- ---------- ---------- ----------- ----------- --------- ---------- --------- ---------- --------- --------- ---------- -----------
  **DILI, *n*(%)**       95 (94)    60 (61)    82 (80)    102 (100)   55 (54)    98 (96)    102 (100)   102 (100)   41 (40)   62 (61)    31 (30)   99 (97)    30 (29)   41 (40)   93 (91)    102 (100)
  **Controls, *n*(%)**   212 (94)   138 (61)   194 (86)   226 (100)   128 (57)   210 (93)   226 (100)   226 (100)   83 (37)   137 (61)   74 (33)   211 (93)   72 (32)   88 (39)   212 (94)   226 (100)

Among the DILI cases 21.6% were homozygous for the A haplotype (AA genotype) while 78.4% contained a B haplotype (Bx: AB or BB genotypes). The corresponding genotype distribution in the control subjects were 21.2 and 78.8%, respectively. Hence, no significant difference in genotype distribution was found between the two groups. The determined genotypes translated into 27 different gene profiles in the DILI patients and 46 in the controls. Nineteen of the gene profiles were present in both groups, while 8 were specific to the DILI patients and 27 to the controls (**Figure [1](#F1){ref-type="fig"}**). The individual DILI-specific genotypes demonstrated frequencies of 0.1--2.0%, while the individual control-specific genotypes had frequencies of 0.4--2.2%. Despite the relatively low number of 'group-specific' genotypes, the DILI group presented a significantly smaller proportion of individuals with DILI-specific genotypes compared to that of controls with control-specific genotypes (8.8% vs. 19%, *p* = 0.024).

![**KIR genotype distribution in 102 Spanish amoxicillin-clavulanate--induced liver injury patients and 226 controls.** Genotype IDs refer to ID numbers assigned by the Allele Frequency Net Database ([www.allelefrequencies.net](http://www.allelefrequencies.net)). The presence and absence of a KIR gene are indicated by a shaded and white box, respectively.](fphar-07-00280-g001){#F1}

None of the individual Bx genotypes present in both groups were found to be significantly different with respect to frequency in the DILI group compared to the controls. The most frequent gene profile among the Bx haplotype carriers contained *3DL1, 2DL1, 2DL3, 2DS4, 2DL2, 2DS2*, and *2DP1* in addition to the four framework loci, and was present in 15.7% of the DILI patients and 14.2% of the controls (**Figure [1](#F1){ref-type="fig"}**). Of the AA haplotype carriers with *2SD4* as the only activating receptor, 54.5% of the DILI patients and 60.4% of the controls where homozygous for the 22 base pair deletion in the *2SD4* gene, which subsequently lead to a haplotype without any aKIR receptor. In addition, 45.5 and 35.4% of the DILI and control AA haplotype carriers, respectively, were found to be heterozygous for same deletion.

Activating KIR genes have been associated with increased susceptibility to certain diseases, in particular autoimmune related disorders. Hence, we compared DILI patients and controls with respect to the total number of aKIR genes in each subject. *KIR2DL4* was not included in this analysis, as it was present in all study subjects and is believed to have both inhibitory and activating functions. Furthermore, presence of the 22 bp deletion in exon 5 causing a truncated KIR2DS4 protein was taken into consideration. Hence, subjects homozygous for the deletion allele and with no other aKIR genes were considered as having no aKIRs. One single aKIR gene was most frequently seen among both DILI patients (21.6%) and controls (20.8%), followed by four aKIR genes in the DILI (16.7%) and five aKIR genes in the control group (16.4%). The presence of six aKIR genes occurred most infrequently in both the groups, although the proportion was slightly higher among the DILI patients (4.9% vs. 2.6%). No statistically significant differences were found comparing DILI patients and controls classified by total number of aKIR genes per subject (**Figure [2](#F2){ref-type="fig"}**).

![**Total number of activating KIR genes (2DS1, 2DS2, 2DS3, 2DS4, 2DS5, and 3DS1) present in 102 Spanish amoxicillin-clavulanate--induced liver injury patients and 226 controls.** Only full-length 2DS4 is considered as an activating KIR, while the presence of 2DS4 with a 22 base pair deletion in exon 5 causing a truncated KIR2DS4 is not.](fphar-07-00280-g002){#F2}

To determine any potential effects of KIR genes on disease phenotype, the presence of KIR genes was also analyzed in the AC DILI cohort stratified by pattern of liver injury. No significant differences were found in the distribution of individual KIR genes between patients presenting with hepatocellular, cholestatic and mixed type of liver injury compared with the controls (data not shown).

HLA Ligand Distribution
-----------------------

All patients and controls were genotyped for the HLA class I loci (A, B, and C) in order to determine the distribution of epitopes C1, C2, and Bw4 as well as the allele groups A3/A11 and B27, which act as ligands for different KIR receptors. Phenotype distributions of the HLA ligands are presented in **Table [3](#T3){ref-type="table"}**. HLA C1 was more frequent than C2 and in both DILI patients (83% vs. 66%) and controls (78% vs. 73%), though the difference was more pronounced among the DILI patients. Sixty percent of the DILI patients contained at least one copy of the HLA-B Bw4 motif compared to 65% in the controls. The distribution of Bw4-Thr80 and Bw4-Ile80 motifs was relatively equal with 36% vs. 33% in the DILI patients and 37% vs. 38% in the control subjects, respectively. The proportion of Bw4 containing HLA-A allele carriers was slightly higher in the control subject compared to DILI patients (27% vs. 18%), while 31% of the DILI patients contained HLA-A3 or A11 alleles compared to 26% of the controls. In addition to A3 and A11, B27 has also been reported to be a potential KIR3DL2 ligand. The distribution of B27 carriers was comparable between the two study populations (3.9% vs. 5.8%). None of the analyzed ligands differed significantly with respect to carrier distributions between DILI cases and controls.

###### 

Phenotype distribution of HLA class I KIR ligands in 102 Spanish amoxicillin-clavulanate--induced liver injury patients and 226 controls.

  HLA class I       DILI, *n*(%)   Controls, *n*(%)
  ----------------- -------------- ------------------
  HLA-C1            85 (83)        176 (78)
  HLA-C2            67 (66)        164 (73)
  C1/C1             35 (34)        62 (27)
  C2/C2             17 (17)        50 (22)
  C1/C2             50 (49)        114 (50)
  HLA-B Bw4         61 (60)        147 (65)
  HLA-B Bw4/Bw4     18 (18)        44 (19)
  HLA-B Bw4-Thr80   36 (35)        83 (37)
  HLA-B Bw4-Ile80   34 (33)        85 (38)
  HLA-A Bw4^∗^      18 (18)        60 (27)
  HLA-A3 or A11     32 (31)        59 (26)
  HLA-B27           4 (3.9)        13 (5.8)

∗

HLA-A

∗

23:01, 24:02, and 32:01.

KIR Receptor-HLA Ligand Distributions
-------------------------------------

The KIR receptors bind to specific HLA ligands. Hence the combination of KIR genes and corresponding HLA ligands present in the subjects was also analyzed. The most frequently found receptor-ligand combinations in the DILI patients were 2DL3 + C1 (67%) and 3DL1 + Bw4 motif (67%), while 2DL1 + C2 (69%) and 3DL1 + Bw4 motif (69%) predominated in the controls. In contrast, 2DS4 with at least one copy of the full length gene combined with HLA A11 alleles was the least frequently found receptor-ligand combination in both the DILI (3.9%) and the control (4.9%) group. No significant differences in phenotype distribution of the analyzed KIR gene and HLA ligand combinations were found between DILI patients and controls (**Table [4](#T4){ref-type="table"}**).

###### 

Phenotype distribution of KIR genes and HLA ligands in 102 Spanish DILI patients and 226 controls.

  KIR + HLA ligands, *n*(%)   DILI, *n*(%)   Controls, *n*(%)
  --------------------------- -------------- ------------------
  **Inhibitory**                             
  2DL1 + C2                   63 (62)        156 (69)
  2DL2 + C1                   51 (50)        108 (48)
  2DL3 + C1                   68 (67)        150 (66)
  3DL1 + Bw4^∗^               68 (67)        157 (69)
  3DL1 + Bw4 (A)^a^           18 (18)        57 (25)
  3DL1 + Bw4 (B)^b^           58 (57)        135 (60)
  3DL1 + Bw4 Thr80            34 (33)        77 (34)
  3DL1 + Bw4 Ile80^b^         32 (31)        77 (34)
  3DL2 + A3/A11/B27           36 (35)        66 (29)
  **Activating**                             
  2DS1 + C2                   27 (26)        61 (27)
  2DS2 + C1                   53 (52)        106 (47)
  2DS2 + A11                  6 (5.9)        23 (10.2)
  2DS4^\#^ + A11              4 (3.9)        11 (4.9)
  3DS1 + Bw4 motif^∗^         27 (26)        62 (27)
  3DS1 + Bw4 (A)^a^           9 (9)          25 (11)
  3DS1 + Bw4 (B)^b^           22 (22)        52 (23)
  3DS1 + Bw4 Thr80            12 (12)        30 (13)
  3DS1 + Bw4 Ile80^b^         12 (12)        30 (13)

∗

HLA-A and B alleles,

a

HLA-A alleles only,

b

HLA-B alleles only,

\#

Homozygots and hetrozygots for the full length allele only.

Discussion
==========

Natural killer cells are enriched in the liver, comprising 25--40% of intrahepatic lymphocytes in normal adult livers ([@B29]). While these cells play an important role in liver diseases by inhibiting viral infection, tumor cell growth and liver fibrosis, they can also be harmful causing hepatocellular damage and inhibiting liver regeneration if not controlled properly. Impaired regulation of NK cell activity is thought to contribute to hepatic diseases such as autoimmune hepatitis, primary biliary cirrhosis and sclerosing cholangitis ([@B29]). The fact that intrahepatic NK cells exhibit higher level of cytotoxicity and increased expression of cytotoxic mediators compared to peripheral NK cells highlights the importance of adequate regulation of NK cell activity ([@B15]). Due to the crucial role of KIR receptors in NK cell activity regulation, KIR genotype analyses have been performed across various conditions, including hepatic diseases, to elucidate the potential contribution of KIR variability in disease susceptibility. In this study, we have analyzed KIR and HLA polymorphisms with regards to AC DILI susceptibility. This is to our knowledge the first KIR analysis focusing on DILI. We did not find any significant differences in the frequency of individual KIR genes between DILI cases and controls. Furthermore, carrier frequencies in the current control group were similar to those of independent Spanish subjects previously published ([@B12]). One must also keep in mind that not only the KIR gene repertoire varies between individuals but that each KIR gene is also highly polymorphic. There are currently 753 different KIR alleles in total present in the IPD-KIR database ([@B22]). Hence, analyzing only presence or absence of KIR genes could obscure existing allele associations.

The presence of aKIRs is generally more variable than that of iKIRs. It has been suggested that the total number of aKIRs could affect disease susceptibility as augmented signals from multiple aKIR receptors might exacerbate the activation of NK cells and T cell subsets against self-antigens leading to disease conditions ([@B3]). Hence, we compared the total number of aKIRs in individual DILI patients and controls, but did not find any significant differences in the proportion of subjects classified by aKIRs, ranging from 0 to 6 different types of activating receptors. As associations between dominant aKIR repertoires and disease susceptibility detected to date are mainly limited to autoimmune conditions, such as lupus erythematosus, Vogt--Koyanagi--Harada syndrome, multiple sclerosis, Hashimoto's thyroiditis and autoimmune hepatitis ([@B14]; [@B17]; [@B8]; [@B3]; [@B18]) a dominance of aKIR receptors may be less important in AC DILI. Nevertheless, autoimmune conditions can also be negatively associated with aKIRs as demonstrated for pemphigus foliaceus. Here the presence of more than three aKIR genes appears to play a protective role, which highlights the fact that the role of aKIR dominance is not general but dependent on the underlying mechanism of the condition in question ([@B4]).

Similar to the lack of association between aKIRs and DILI susceptibility, the proportions of AA and Bx genotype carriers were comparable between patients and controls. AA1 was the most frequent genotype in both groups. The Bx genotypes translated to 26 and 45 different genotypes in the DILI patients and controls, respectively, with 18 Bx genotypes being present in both groups with similar frequencies. The three most frequent Bx genotypes in both the DILI and control group were Bx4, Bx5, and Bx2, which together made up 40% and 35% of the Bx genotype carriers in the two populations, respectively. The individual genotype distributions of Bx4, Bx5, and Bx2 were similar to those previously observed in different Spanish and other European populations^[2](#fn02){ref-type="fn"}^. These three genotypes are also among the most common KIR genotypes worldwide ([@B13]). In the current study, we found nine Bx genotypes that were specific to the DILI patients and 27 that were only found in the control groups. However, it is unlikely that the DILI-specific genotypes would have any bigger impact on AC DILI susceptibility due to the small number of patients that were found to be carriers of these KIR genotypes. Similarly, the low frequency of the individual control-specific genotypes does not speak in favor of these genotypes having any protective effect against AC DILI.

The function of KIR receptors depends on the presence of appropriate HLA ligands on the target cell in order for correct signaling and NK cell activity to occur. Hence, we analyzed the presence of currently identified HLA class I ligands in our patient and control cohorts but did not find any significant differences between the two groups. HLA ligands have, however, been associated with liver disease progression. For example, HLA-C1 homozygosity and presence of the HLA-Bw4 I80 variant have been associated with better overall survival of hepatitis C virus-related hepatocellular carcinoma after curative treatment ([@B6]), while HLA-C2 homozygosity has been associated with increased risk of hepatitis C virus infection treatment failure ([@B28]). Evidence of enhanced risk of developing primary sclerosing cholangitis in HLA-Bw6 and HLA-C1 homozygotes has also been presented ([@B16]).

Considering KIR and HLA repertoires simultaneously has likewise been explored in search for the role of NK cells in disease conditions. Our analysis did not reveal any significant difference in concurrent KIR receptor and HLA ligand carriage between DILI patients and control subjects. The KIR-HLA combinations considered in this study were based on identified ligands to date. However, the current understanding of KIR ligands is not complete and presently unknown KIR receptor-HLA ligand interactions could possibly influence DILI susceptibility and should therefore not be overlooked. Furthermore, it has been suggested that different KIR allele products can have different affinity for the same HLA ligand ([@B7]), which could lead to differences in NK cell activity regulation. As our KIR analysis was limited to presence or absence of KIR receptors, this aspect was consequently not evaluated.

In summary, in the first exploratory study of 102 Spanish AC DILI cases and 226 controls no significant differences in KIR repertoires and corresponding HLA class I ligand profiles were detected. These results are suggestive of KIRs not being major risk factors for AC DILI susceptibility. However, as the mechanism of KIR receptors is not completely elucidated to date and NK cell activity regulation systems additional to KIR are present, a potential role for NK cells activity in DILI should not be completely dismissed. Further studies on the level of KIR receptor expression and cytokine production are warranted in this area.
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